Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 9/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.49 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268182 | 0.93 | BCL6 (0.50) | PTK2CRBNBTKALKEGFR | |
| SCHEMBL31595444 | 0.93 | BCL6 (0.50) | PTK2CRBNBTKALKEGFR | |
| SCHEMBL31595536 | 0.93 | BCL6 (0.50) | PTK2CRBNBTKALKEGFR | |
| SCHEMBL23267556 | 0.93 | BCL6 (0.50) | PTK2CRBNBTKALKEGFR | |
| SCHEMBL23267647 | 0.92 | BCL6 (0.50) | PTK2CRBNBTKALKEGFR | |
| SCHEMBL23267655 | 0.92 | CRBN (0.47) | PTK2CRBNBTKALKEGFR | |
| SCHEMBL29874152 | 0.92 | BCL6 (0.57) | PTK2CRBNBTKALKAR | |
| SCHEMBL23249960 | 0.92 | BCL6 (0.57) | PTK2CRBNBTKALKAR | |
| SCHEMBL23249916 | 0.92 | BCL6 (0.57) | PTK2CRBNBTKALKAR | |
| SCHEMBL29874253 | 0.92 | BCL6 (0.57) | PTK2CRBNBTKALKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | PTK2 3371/4885CRBN 5/4885BTK 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.